Immunogenicity and reactogenicity of a reduced schedule of a 4-component capsular group B meningococcal vaccine: a randomized controlled trial in infants

<strong>Background<br></strong> The 4-component capsular group B meningococcal vaccine (4CMenB) was licensed as a 4-dose infant schedule but introduced into the United Kingdom as 3 doses at 2, 4, and 12 months of age. We describe the immunogenicity and reactogenicity of the 2 + 1 s...

Mô tả đầy đủ

Chi tiết về thư mục
Những tác giả chính: Valente Pinto, M, O'Connor, D, Galal, U, Clutterbuck, EA, Robinson, H, Plested, E, Bibi, S, Camara Pellisso, S, Hughes, H, Kerridge, S, Mujadidi, YF, Findlow, H, Borrow, R, Snape, MD, Pollard, AJ
Định dạng: Journal article
Ngôn ngữ:English
Được phát hành: Oxford University Press 2020